NanoVibronix (NAOV) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 14, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-36445
Entity Registrant Name	NanoVibronix, Inc
Entity Central Index Key	0001326706
Entity Tax Identification Number	01-0801232
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	525 Executive Blvd.
Entity Address, City or Town	Elmsford
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10523
City Area Code	(914)
Local Phone Number	233-3004
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	NAOV
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		27,997,793

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 1,972	$ 7,737
Trade receivables, net	226	200
Other accounts receivable and prepaid expenses	1,238	230
Inventory, net	1,553	175
Total current assets	4,989	8,342
Non-current assets:
Fixed assets, net	8	5
Other assets	7	19
Severance pay fund	178	207
Operating lease right-of-use assets, net	28	49
Total non-current assets	221	280
Total assets	5,210	8,622
Current liabilities:
Trade payables	41	87
Other accounts payable and accrued expenses	1,646	1,723
Deferred revenues		44
Operating lease liabilities - current	28	49
Total current liabilities	1,715	1,903
Non-current liabilities:
Accrued severance pay	222	253
Deferred licensing income	119	153
Total liabilities	2,056	2,309
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock of $0.001 par value - Authorized: 40,000,000 shares at September 30, 2022 and December 31, 2021; Issued and outstanding: 27,997,793 shares at both September 30, 2022 and December 31, 2021	28	28
Additional paid in capital	63,449	63,162
Accumulated other comprehensive income	3	60
Accumulated deficit	(60,326)	(56,937)
Total stockholders’ equity	3,154	6,313
Total liabilities and stockholders’ equity	5,210	8,622
Series C Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value
Series D Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value
Series E Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value
Series F Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	27,997,793	27,997,793
Common stock, shares outstanding	27,997,793	27,997,793
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series D Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	506	506
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series E Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,999,494	1,999,494
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series F Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	40,000	40,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenues	$ 97	$ 499	$ 854	$ 920
Cost of revenues	17	271	387	407
Gross profit	80	228	467	513
Operating expenses:
Research and development	49	50	176	178
Selling and marketing	217	245	760	852
General and administrative	738	801	2,835	2,656
Total operating expenses	1,004	1,096	3,771	3,686
Loss from operations	(924)	(868)	(3,304)	(3,173)
Financial expenses, net	(16)	(23)	(47)	(29)
Change in fair value of derivative liabilities		(5,714)		(6,956)
Gain on purchase of warrants				64
Warrant modification expense				(1,627)
Loss before taxes on income	(940)	(6,605)	(3,351)	(11,721)
Income tax expense	(15)	(70)	(38)	(87)
Net loss available to common stockholders	$ (955)	$ (6,675)	$ (3,389)	$ (11,808)
Basic and diluted net loss available for holders of common stock	$ (0.03)	$ (0.26)	$ (0.12)	$ (0.47)
Weighted average common shares outstanding:
Basic and diluted	27,997,793	26,096,957	27,997,793	25,014,919
Comprehensive loss:
Change in foreign currency translation adjustments	$ (6)	$ 1	$ (57)	$ (7)
Comprehensive loss available to common stockholders	$ (999)	$ (6,674)	$ (3,446)	$ (11,815)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] Series D Preferred Stock [Member]	Preferred Stock [Member] Series E Preferred Stock [Member]	Preferred Stock [Member] Series F Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 1		$ 1		$ 22	$ 44,959	$ 66	$ (42,655)	$ 2,394
Beginning balance, shares at Dec. 31, 2020	666,667	153	875,000		21,246,523
Stock-based compensation						114			114
Issuance of common stock for cash, net					3				3
Exercise of warrants					$ 2	7,050			7,052
Exercise of warrants, shares					5,056,603
Conversion of preferred stock to common stock
Conversion of preferred stock to common stock, shares			(875,000)		875,000
Reclass from liability to equity						10,963			10,963
Other comprehensive loss							(7)		(7)
Net loss								(11,808)	(11,808)
Ending balance, value at Sep. 30, 2021	$ 1		$ 1		$ 27	63,086	59	(54,463)	8,711
Ending balance, shares at Sep. 30, 2021	666,667	153			27,178,126
Beginning balance, value at Jun. 30, 2021	$ 1		$ 1		$ 24	51,867	59	(47,788)	4,164
Beginning balance, shares at Jun. 30, 2021	666,667	153	875,000		24,109,634
Stock-based compensation						35			35
Issuance of common stock for cash, net					3				3
Exercise of warrants						3,558			3,558
Exercise of warrants, shares					2,193,491
Conversion of preferred stock to common stock
Conversion of preferred stock to common stock, shares			(875,000)		875,000
Reclass from liability to equity						7,626			7,626
Other comprehensive loss
Net loss								(6,675)	(6,675)
Ending balance, value at Sep. 30, 2021	$ 1		$ 1		$ 27	63,086	59	(54,463)	8,711
Ending balance, shares at Sep. 30, 2021	666,667	153			27,178,126
Beginning balance, value at Dec. 31, 2021					$ 28	63,162	60	(56,937)	6,313
Beginning balance, shares at Dec. 31, 2021					27,997,793
Stock-based compensation						287			287
Exercise of warrants						135			135
Other comprehensive loss							(57)		(57)
Net loss								(3,389)	(3,389)
Reversal of warrants						(135)			(135)
Ending balance, value at Sep. 30, 2022					$ 28	63,449	3	(60,326)	3,154
Ending balance, shares at Sep. 30, 2022					27,997,793
Beginning balance, value at Jun. 30, 2022					$ 28	63,468	9	(59,371)	4,134
Beginning balance, shares at Jun. 30, 2022					27,997,793
Stock-based compensation						116			116
Other comprehensive loss							(6)		(6)
Net loss								(955)	(955)
Reversal of warrants						(135)			(135)
Ending balance, value at Sep. 30, 2022					$ 28	$ 63,449	$ 3	$ (60,326)	$ 3,154
Ending balance, shares at Sep. 30, 2022					27,997,793

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (3,389)	$ (11,808)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1	1
Stock-based compensation	287	114
Warrant modification expense		1,627
Change in fair value of equity investment	12	9
Change in fair value of derivative liabilities		7,148
Gain on purchase of warrants		(64)
Changes in operating assets and liabilities:
Trade receivable	(26)	(4)
Other accounts receivable and prepaid expenses	(1,008)	(330)
Inventory	(1,378)	(56)
Trade payables	(46)	(82)
Other accounts payable and accrued expenses	(77)	(294)
Deferred revenue	(78)	237
Accrued severance pay, net	(2)	(2)
Net cash used in operating activities	(5,704)	(3,504)
Cash flows from investing activities:
Purchases of property plant and equipment	(4)	(3)
Net cash used in investing activities	(4)	(3)
Cash flows from financing activities:
Proceeds from exercise of warrants		4,968
Buy back of warrants from investors		(388)
Net cash provided by financing activities		4,580
Effects of currency translation on cash	(57)	(7)
Net (decrease) increase in cash	(5,765)	1,066
Cash at beginning of period	7,737	7,533
Cash at end of period	1,972	8,599
Supplemental non-cash financing and investing activities:
Shares issued from exercise of warrants previously classified as derivative liability		2,087
Reclassification liability to equity due to increase in authorized shares		$ 10,963

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 – DESCRIPTION OF BUSINESS NanoVibronix, Inc. (the “Company”), a Delaware corporation, commenced operations on October 20, 2003 and is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals. The Company’s principal research and development activities are conducted in Israel through its wholly owned subsidiary, NanoVibronix (Israel 2003) Ltd., a company registered in Israel, which commenced operations in October 2003.

LIQUIDITY AND PLAN OF OPERATION

LIQUIDITY AND PLAN OF OPERATIONS	9 Months Ended
	Sep. 30, 2022
Liquidity And Plan Of Operations
LIQUIDITY AND PLAN OF OPERATIONS	NOTE 2 – LIQUIDITY AND PLAN OF OPERATIONS The Company’s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the receipt of additional financing until profitability is achieved. During the three quarters of 2022, the Company’s cash used in operations was $ 5,704 1,972

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation and principles of consolidation The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for the interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. The unaudited condensed consolidated financial statements include the accounts of all subsidiaries in which the Company holds a controlling financial interest as of the financial statement date. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Unaudited interim financial information In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the financial position and results of operations of the Company. These consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2021, as found in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2022, as amended on May 2, 2022. The balance sheet for December 31, 2021 was derived from the Company’s audited financial statements for the year ended December 31, 2021. The results of operations for the periods presented are not necessarily indicative of results that could be expected for the entire fiscal year due to seasonality and other factors. Certain information and footnote disclosures normally included in the consolidated financial statements in accordance with U.S. GAAP have been omitted in accordance with the rules and regulations of the SEC for interim reporting. Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company believe that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Foreign currency translation Non-U.S. dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income, as appropriate. The cumulative translation loss for the nine 30, 2022 and 2021 were $ 57 7 Revenue recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements. Revenue from product sales is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers. Revenues from sales to distributors are recognized at the time the products are delivered to the distributors (“sell-in”). The Company does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 4 – STOCKHOLDERS’ EQUITY Common stock The common stock confers upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the right to receive dividends, if declared, and to participate in the distribution of the surplus assets and funds of the Company in the event of liquidation, dissolution or winding up of the Company. Series F Preferred Stock On September 13, 2022, the board of directors of the Company (the “Board”), declared a dividend of one one-thousandth of a share of Series F Preferred Stock, par value $ 0.001 0.001 Stock-based compensation and options During the nine-month period ended September 437,500 180,000 116 287 99 306 0 13,845 The fair value for options granted in the third quarter of 2022 and 2021 is estimated at the date of grant using a Black-Scholes-Merton options pricing model with the following underlying assumptions: SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED 2022 2021 Price at valuation $ 0.45 $ 1.04 Exercise price $ 0.45 $ 1.04 Risk free interest 3.58 % 0.49 % Expected term (in years) 5 5 Volatility 125.3 % 81.5 % The total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the following table. SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Research and development 2 5 5 15 Selling and marketing 6 10 18 41 General and administrative 108 84 264 250 Total $ 116 $ 99 $ 287 $ 306 As of September 30, 2022, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $ 395 2.05 Warrant exercises and modification On December 2, 2020, we entered into a Securities Purchase Agreement with certain institutional and accredited investors pursuant to which the Company issued and sold to such investors in a private placement an aggregate of (i) 5,914,285 0.70 2,657,144 0.699 6.0 5.4 1,657,144 0.001 On January 21, 2021, Company entered into letter agreements (the “Letter Agreements”) with certain existing accredited investors to exercise certain outstanding warrants (the “Existing Warrants”) to purchase up to an aggregate of 1,205,968 1.165 1,205,967 1.04 1.4 The New Warrants were accounted for in warrant modification expense, which was measured at the amount equal to the incremental value reflecting the change in the fair value of the warrants before and after the Warrant Amendment. Accordingly, warrant modification expense in the amount of $ 1,627 On June 14, 2022, the Company issued warrants to two sales consultants to purchase 250,000 June 14, 2029 1.00 135,000 On September 30, 2022, the Company and the two sales consultants mutually agreed to cancel the latter’s annual stock warrants to purchase 250,000 135,000 In estimating the warrants’ fair value, the Company used the following assumptions: SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS Risk free interest 0.34 % Dividend yield 0 % Volatility 60.7 % Contractual term (in years) 7

LOSS PER SHARE APPLICABLE TO CO

LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER	NOTE 5 – LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER Basic net loss per common share (“Basic EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. All outstanding stock options and warrants for the three and nine months ended September 30, 2022 and 2021 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all periods presented. The following table summarizes the Company’s securities, in common stock equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE September 30, 2022 September 30, 2021 Series D Preferred Stock - 153,000 Stock Options - employee and non-employee 2,977,499 1,914,699 Warrants 2,309,347 2,309,347 Total 5,286,846 4,224,199 The diluted loss per share equals basic loss per share in the three and nine months ended September 30, 2022 and 2021 because the Company had a net loss and the impact of the assumed exercise of stock options and the vesting of restricted stock would have been anti-dilutive.

GEOGRAPHIC INFORMATION AND MAJO

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA	NOTE 6 – GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA Summary information about geographic areas: The Company manages its business on the basis of one SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 United States $ 90 $ 490 $ 828 $ 874 Europe 6 4 13 15 Asia - 2 9 4 New Zealand 1 3 4 15 Canada - - - 12 Total $ 97 $ 499 $ 854 $ 920 The Company’s largest customer is Ultra Pain Products, Inc. (UPPI) who accounted for with revenue equal to $ 483,000 57 nil

OTHER ASSETS

OTHER ASSETS	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
OTHER ASSETS	NOTE 7 – OTHER ASSETS On April 9, 2020, pursuant to a licensing agreement entered in March 2020, the Company received 10 127,000 0.19 SCHEDULE OF WARRANTS ASSUMPTIONS Price at valuation $ 0.06 Exercise price $ 0.19 Risk free interest 3.97 % Expected term (in years) 8 Volatility 137.7 % The Company considers this to be level 3 inputs and is valued at each reporting period. For the three and nine months ended September 30, 2022, changes in the fair value of these warrants amounted to $ 2 12 7 7 9 Financial Instruments Measured at Fair Value on a Recurring Basis The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows: ● Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets; ● Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and ● Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions. There were no transfers from Level 3 during the quarters ended September 30, 2022 and 2021. The following table presents changes in Level 3 asset and liability measured at fair value for the quarters ended September 30, 2022 and 2021: SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE Asset Balance – December 31, 2020 $ 25 Fair value adjustments – Sanuwave warrants (2 ) Balance – March 31, 2021 $ 23 Fair value adjustments – Sanuwave warrants - Balance – June 30, 2021 $ 23 Fair value adjustments – Sanuwave warrants (7 ) Balance – September 30, 2021 16 Balance – December 31, 2021 19 Fair value adjustments – Sanuwave warrants (2 ) Balance – March 31, 2022 $ 17 Fair value adjustments – Sanuwave warrants (8 ) Balance – June 30, 2022 $ 9 Fair value adjustments – Sanuwave warrants (2 ) Balance – September 30, 2022 7 The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy: SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Level I Level II Level III Total Fair Value Measurements as of September 30, 2022 Level I Level II Level III Total Asset: Other assets $ - $ - $ 7 $ 7 Fair Value Measurements as of December 31, 2021 Level I Level II Level III Total Asset: Other assets $ - $ - $ 19 $ 19

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES Other Risks On March 12, 2020, the World Health Organization declared COVID-19 to be a pandemic, and the COVID-19 pandemic has resulted in significant financial market volatility and uncertainty. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, on our business, results of operations and financial conditions, and on the market price of our common shares. In addition, U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. A continuation or worsening of the levels of market disruption and volatility could have an adverse effect on our ability to access capital, on our business, results of operations and financial condition, and on the market price of our common shares. Lastly, inflation, as well as some of the measures taken by or that may be taken by the governments in countries where we operate in an attempt to curb inflation may have negative effects on the economies of those countries generally. If the United States or other countries where we operate experience substantial inflation in the future, our business may be adversely affected. This could have a material adverse effect on our business, financial condition, results of operations, or cash flows. Specifically, our existing distributor agreements limit the amount that we can increase the price that we sell our products to the distributors. Accordingly, an inflationary environment, including factors such as increasing freight and materials prices, could make it less profitable for us to do business. Pending litigation On February 26, 2021, Protrade Systems, Inc. (“Protrade”) filed a Request for Arbitration (the “Request”) with the International Court of Arbitration (the “ICA”) of the International Chamber of Commerce alleging the Company is in breach of an Exclusive Distribution Agreement dated March 7, 2019 (the “Agreement”) between Protrade and the Company. Protrade alleges, in part, that the Company has breached the Agreement by discontinuing the manufacture of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $ 3 On March 15, 2022, the arbitrator issued a final award, which, although denied all Protrade’s claims, nevertheless awarded Protrade about $ 1.5 On April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the Award. On April 13, 2022, the Company submitted an application to the ICA seeking to correct an error in the award based on the evidence that the Company only sold 2-3 reusable patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the award, denied the application. On July 22, 2022, the Company filed a motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority, that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular, the Company averred in its motion that Protrade’s witness made false statements in arbitration, and that the arbitrator resolved a claim that was never raised by Protrade and that has no factual basis. On October 3, 2022, the court issued a decision granting Protrade its petition to confirm the Award and denying the cross-motion. On November 9, 2022, the Company filed a motion to re-argue and re-plead the arbitration decision based on additional information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate Division, Second Department. The Company expects to continue to vigorously pursue its opposition to the award in all appropriate fora.

RELATED PARTY TRANSACTION

RELATED PARTY TRANSACTION	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTION	NOTE 9 – RELATED PARTY TRANSACTION The firm of FisherBroyles LLP is handling our Protrade litigation and appeals. For the nine months ended September 30, 2022, we have been billed and paid legal fees from Fisher Broyles amounting to $232,703 and recorded as part of “General and administrative expenses” in the condensed consolidated statements of operations. As has been previously disclosed, one of our board members, Aurora Cassirer, is a partner at Fisher Broyles. Ms. Cassirer does not provide any legal services or legal advice to the Company .

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 – SUBSEQUENT EVENTS Series F Preferred Stock On September 13, 2022, the Board declared a dividend of one one-thousandth of a share of Series F Preferred Stock, par value $ 0.001 0.001 Each share of Series F Preferred Stock entitles the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series F Preferred Stock has a ratable number of votes). Thus, each one-thousandth of a share of Series F Preferred Stock entitles the holder thereof to 1,000 votes. Unless otherwise provided on any applicable proxy or ballot with respect to the voting on the Reverse Stock Split or the Adjournment Proposal, the vote of each share of Series F Preferred Stock (or fraction thereof) entitled to vote on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal will be cast in the same manner as the vote, if any, of the share of common stock (or fraction thereof) in respect of which such share of Series F Preferred Stock (or fraction thereof) was issued as a dividend is cast on the Reverse Stock Split, the Adjournment Proposal or such other matter, as applicable, and the proxy or ballot with respect to shares of common stock held by any holder on whose behalf such proxy or ballot is submitted will be deemed to include all shares of Series F Preferred Stock (or fraction thereof) held by such holder. Holders of Series F Preferred Stock will not receive a separate ballot or proxy to cast votes with respect to the Series F Preferred Stock on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split. Each share of Series F Preferred Stock redeemed in any redemption described above will be redeemed in consideration for the right to receive an amount equal to $ 0.10 No shares of Series F Preferred Stock may be transferred by the holder thereof except in connection with a transfer by such holder of any shares of common stock held by such holder, in which case a number of one one-thousandths (1/1,000ths) of a share of Series F Preferred Stock equal to the number of shares of common stock to be transferred by such holder will be automatically transferred to the transferee of such shares of common stock. The holders of Series F Preferred Stock, as such, are not entitled to receive dividends of any kind. The Certificate of Designation was filed with the Delaware Secretary of State and became effective on September 14, 2022. As described in the proxy statement filed on October 31, 2022, holders of our common stock and Series F Preferred Stock as of the close of business on October 17, 2022, are entitled to vote on the amendment to the Company’s Certificate of Incorporation to effect, at the discretion of the Company’s Board but prior to the six-month anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-50

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for the interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. The unaudited condensed consolidated financial statements include the accounts of all subsidiaries in which the Company holds a controlling financial interest as of the financial statement date. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Unaudited interim financial information	Unaudited interim financial information In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the financial position and results of operations of the Company. These consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2021, as found in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2022, as amended on May 2, 2022. The balance sheet for December 31, 2021 was derived from the Company’s audited financial statements for the year ended December 31, 2021. The results of operations for the periods presented are not necessarily indicative of results that could be expected for the entire fiscal year due to seasonality and other factors. Certain information and footnote disclosures normally included in the consolidated financial statements in accordance with U.S. GAAP have been omitted in accordance with the rules and regulations of the SEC for interim reporting.
Use of estimates	Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company believe that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Foreign currency translation	Foreign currency translation Non-U.S. dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income, as appropriate. The cumulative translation loss for the nine 30, 2022 and 2021 were $ 57 7
Revenue recognition	Revenue recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements. Revenue from product sales is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers. Revenues from sales to distributors are recognized at the time the products are delivered to the distributors (“sell-in”). The Company does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED	The fair value for options granted in the third quarter of 2022 and 2021 is estimated at the date of grant using a Black-Scholes-Merton options pricing model with the following underlying assumptions: SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED 2022 2021 Price at valuation $ 0.45 $ 1.04 Exercise price $ 0.45 $ 1.04 Risk free interest 3.58 % 0.49 % Expected term (in years) 5 5 Volatility 125.3 % 81.5 %
SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES	The total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the following table. SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Research and development 2 5 5 15 Selling and marketing 6 10 18 41 General and administrative 108 84 264 250 Total $ 116 $ 99 $ 287 $ 306
SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS	In estimating the warrants’ fair value, the Company used the following assumptions: SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS Risk free interest 0.34 % Dividend yield 0 % Volatility 60.7 % Contractual term (in years) 7

LOSS PER SHARE APPLICABLE TO _2

LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE	The following table summarizes the Company’s securities, in common stock equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE September 30, 2022 September 30, 2021 Series D Preferred Stock - 153,000 Stock Options - employee and non-employee 2,977,499 1,914,699 Warrants 2,309,347 2,309,347 Total 5,286,846 4,224,199

GEOGRAPHIC INFORMATION AND MA_2

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS	The Company manages its business on the basis of one SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 United States $ 90 $ 490 $ 828 $ 874 Europe 6 4 13 15 Asia - 2 9 4 New Zealand 1 3 4 15 Canada - - - 12 Total $ 97 $ 499 $ 854 $ 920

OTHER ASSETS (Tables)

OTHER ASSETS (Tables)	9 Months Ended
	Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
SCHEDULE OF WARRANTS ASSUMPTIONS	SCHEDULE OF WARRANTS ASSUMPTIONS Price at valuation $ 0.06 Exercise price $ 0.19 Risk free interest 3.97 % Expected term (in years) 8 Volatility 137.7 %
SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE	The following table presents changes in Level 3 asset and liability measured at fair value for the quarters ended September 30, 2022 and 2021: SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE Asset Balance – December 31, 2020 $ 25 Fair value adjustments – Sanuwave warrants (2 ) Balance – March 31, 2021 $ 23 Fair value adjustments – Sanuwave warrants - Balance – June 30, 2021 $ 23 Fair value adjustments – Sanuwave warrants (7 ) Balance – September 30, 2021 16 Balance – December 31, 2021 19 Fair value adjustments – Sanuwave warrants (2 ) Balance – March 31, 2022 $ 17 Fair value adjustments – Sanuwave warrants (8 ) Balance – June 30, 2022 $ 9 Fair value adjustments – Sanuwave warrants (2 ) Balance – September 30, 2022 7
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE	The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy: SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Level I Level II Level III Total Fair Value Measurements as of September 30, 2022 Level I Level II Level III Total Asset: Other assets $ - $ - $ 7 $ 7 Fair Value Measurements as of December 31, 2021 Level I Level II Level III Total Asset: Other assets $ - $ - $ 19 $ 19

LIQUIDITY AND PLAN OF OPERATI_2

LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Liquidity And Plan Of Operations
Net cash used in operating activities	$ 5,704	$ 3,504
Cash balance	$ 1,972

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Gains and losses from foreign currency translation	$ 57	$ 7

SCHEDULE OF FAIR VALUE ASSUMPTI

SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details) - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Equity [Abstract]
Price at valuation	$ 0.45	$ 1.04
Exercise price	$ 0.45	$ 1.04
Risk free interest	3.58%	0.49%
Expected term (in years)	5 years	5 years
Volatility	125.30%	81.50%

SCHEDULE OF STOCK BASED EXPENSE

SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total	$ 116	$ 99	$ 287	$ 306
Research and Development Expense [Member]
Total	2	5	5	15
Selling and Marketing Expense [Member]
Total	6	10	18	41
General and Administrative Expense [Member]
Total	$ 108	$ 84	$ 264	$ 250

SCHEDULE OF FAIR VALUE ASSUMP_2

SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details)	Sep. 30, 2022	Apr. 09, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contractual term (in years)	7 years
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	0.34	3.97
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	0
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input, percentage	60.7	137.7

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2022

Sep. 13, 2022

Jun. 14, 2022

Jan. 21, 2021

Dec. 02, 2020

Jan. 31, 2021

Sep. 30, 2022

Sep. 30, 2021

Jun. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Apr. 09, 2020

Class of Stock [Line Items]

Stock-based compensation expense

$ 116

$ 99

$ 287

$ 306

Warrants exercise price

$ 1

$ 0.19

Purchase of warrants

250,000

250,000

250,000

250,000

Proceeds from Warrant Exercises

4,968

Warrants, modification expense

$ 2

7

12

$ 9

Warrants expire date

Jun. 14, 2029

Increase in additional paid in capital warrants

$ 135,000

$ 135,000

New Warrants [Member]

Class of Stock [Line Items]

Warrants exercise price

$ 1.04

Purchase of warrants

1,205,967

Proceeds from Warrant Exercises

$ 1,400

Warrants, modification expense

$ 1,627

Two Investors [Member] | Warrants [Member]

Class of Stock [Line Items]

Stock issued during period warrants

1,657,144

Warrants exercise price

$ 0.001

Securities Purchase Agreement [Member]

Class of Stock [Line Items]

Gross proceeds from private placement

$ 6,000

Net proceeds from private placement

$ 5,400

Securities Purchase Agreement [Member] | Pre-funded Warrants [Member]

Class of Stock [Line Items]

Sale of stock, number of shares issued

2,657,144

Sale of stock, price per share

$ 0.699

Employee Stock [Member]

Class of Stock [Line Items]

Non-vested stock options granted, unrecognized estimated compensation cost

$ 395

395

$ 395

Non-vested stock options granted, weighted average period

2 years 18 days

Private Placement [Member] | Securities Purchase Agreement [Member]

Class of Stock [Line Items]

Sale of stock, number of shares issued

5,914,285

Sale of stock, price per share

$ 0.70

Employees and Consultants [Member]

Class of Stock [Line Items]

Number of options, granted

437,500

180,000

Stock-based compensation expense

$ 116

$ 99

$ 287

$ 306

Stock-based compensation expense

0

13,845

Accredited Investors [Member] | Warrants [Member]

Class of Stock [Line Items]

Warrants exercise price

$ 1.165

Purchase of warrants

1,205,968

Series F Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, par value

$ 0.001

Series F Common Stock [Member]

Class of Stock [Line Items]

Common stock, par value

$ 0.001

SUMMARY OF COMMON SHARE EQUIVAL

SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	5,286,846	4,224,199
Series D Preferred Stock Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		153,000
Stock Options - Employee and Non-Employee [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	2,977,499	1,914,699
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	2,309,347	2,309,347

SUMMARY OF REVENUE WITHIN GEOGR

SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Total	$ 97	$ 499	$ 854	$ 920
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Total	90	490	828	874
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total	6	4	13	15
Asia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total		2	9	4
NEW ZEALAND
Revenues from External Customers and Long-Lived Assets [Line Items]
Total	1	3	4	15
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
Total				$ 12

GEOGRAPHIC INFORMATION AND MA_3

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)	9 Months Ended
	Sep. 30, 2022 USD ($)
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Revenue, Major Customer [Line Items]
Concentration risk, percentage	57%
Ultra Pain Products Inc [Member]
Revenue, Major Customer [Line Items]
Accounting revenues	$ 483,000

SCHEDULE OF WARRANTS ASSUMPTION

SCHEDULE OF WARRANTS ASSUMPTIONS (Details)	Sep. 30, 2022	Apr. 09, 2020 $ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (in years)	7 years
Price at Valuation [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		0.06
Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		0.19
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.34	3.97
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (in years)		8 years
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	60.7	137.7

SCHEDULE OF CHANGES IN LEVEL 3

SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details) - Derivative Asset [Member] - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021
Offsetting Assets [Line Items]
Balance – June 30, 2022	$ 9	$ 17	$ 19	$ 23	$ 23	$ 25
Fair value adjustments – Sanuwave warrants	(2)	(8)	(2)	(7)		(2)
Balance – September 30, 2022	$ 7	$ 9	$ 17	$ 16	$ 23	$ 23

SCHEDULE OF ASSETS AND LIABILIT

SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Other assets	$ 7	$ 19
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Other assets
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Other assets
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Other assets	$ 7	$ 19

OTHER ASSETS (Details Narrative

OTHER ASSETS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 14, 2022	Apr. 09, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants, term	7 years		7 years
Warrants issued to purchase common stock	250,000		250,000		250,000
Exercise price of warrants per share					$ 1	$ 0.19
Fair value of warrants	$ 2,000	$ 7,000	$ 12,000	$ 9,000
Warrant balance value	$ 7		$ 7
Licensing Agreement [Member] | Sanuwave Health, Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants, term						10 years
Warrants issued to purchase common stock						127,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) $ in Millions	Mar. 15, 2022	Feb. 26, 2021
Arbitrator [Member]
Damages awarded value	$ 1.5
Protrade Systems, Inc [Member]
Protrade claims estimated damages		$ 3

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - $ / shares	Oct. 31, 2022	Sep. 13, 2022	Sep. 30, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Common stock, par value			$ 0.001	$ 0.001
Common Stock [Member]
Subsequent Event [Line Items]
Common stock, par value		$ 0.001
Series F Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, par value		$ 0.001	$ 0.01	$ 0.01
Preferred stock voting rights description		Each share of Series F Preferred Stock entitles the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series F Preferred Stock has a ratable number of votes). Thus, each one-thousandth of a share of Series F Preferred Stock entitles the holder thereof to 1,000 votes.
Redeemed in consideration, value per 100 share		$ 0.10
Series F Preferred Stock [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Reverse stock split	1-for-2 to 1-for-50